Ionis Pharmaceuticals (LTS:0JDI) Valuation Rank


LTS:0JDI Ionis Pharmaceuticals Inc LTS:0JDI
71 GF Score
Price $58.88
GF Value $53.77
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ionis Pharmaceuticals Valuation Rank Related Terms

LTS:0JDI
71GF Score
Ionis Pharmaceuticals Inc LTS:0JDI
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $58.88 is trading 9.5% above its estimated GF Value™ of $53.77. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0JDI:

  • Valuation Rank:
  • GF Value™: $53.77 vs. price of $58.88 (9.5% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for LTS:0JDI

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.88
Price
$53.77
GF Value